Drug distributors win $2.5 billion opioid case in West Virginia

An opioid abuse epidemic that has claimed more than 500,000 lives over the past two decades has spawned more than 3,300 lawsuits against them and other firms.

McKesson, AmerisourceBergen, and Cardinal Health, three major American drug distributors, were found not liable for a West Virginia opioid epidemic, a federal judge concluded on Monday.

U.S. District Court Judge David Faber rejected an attempt by the city of Huntington and Cabell County to force the three largest pharmaceutical distributors to pay $2.5 billion to deal with a drug epidemic in their area.

After a trial that lasted several months and finished last year, Judge Faber ruled that the businesses were not to blame for the excess of opioid painkillers, instead blaming doctors’ “good faith” prescribing judgments for the high amount of medicines they sent to pharmacies.

Even though, from 2006 to 2014, the firms delivered 51.3 million opioid pills to local retail pharmacies, the judge concluded that “there is nothing unreasonable about distributing controlled substances to fill legally written prescriptions.”

Officially, Mayor Steve Williams called the decision “a blow to our city and community” in a statement. The city had attempted to force the firms to pay to fund opioid treatment programs.

“Secure channel to deliver medications of all kinds,” Cardinal Health remarked in response to Judge Faber’s verdict. McKesson said it maintains rigorous measures to prevent the diversion of opioids to criminal channels.

Opioid misuse has resulted in more than 500,000 deaths in the last two decades, with more than 3,300 lawsuits filed by state and municipal governments seeking to hold those and other firms liable.

As a result of the dozens of lawsuits filed against them by state and local governments across the country, the distributors and drugmaker Johnson & Johnson (J&J) agreed last year to pay up to $26 billion.

Communities in West Virginia, which has been heavily struck by the opioid epidemic, decided not to join a national settlement in favor of pursuing a more extensive recovery. Tuesday marks the start of a new trial in West Virginia between the distributors and the state’s residents.

In Oklahoma and California last year, courts rejected similar claims against drugmakers like J&J. Monday’s verdict adds to the mixed record for opioid cases that have gone to trial nationally.

Federal jurors convicted CVS Health Corp, Walgreens Boots Alliance Inc, and Walmart Inc in November of two Ohio counties’ lawsuits against them. In a case brought by the state and two counties, a New York jury found Teva Pharmaceutical Industries Ltd responsible in December.

ShreyaShah

Recent Posts

Festival Trips vs. Vacation Trips: The New Packing List Is Logistics, Not Linen

In 2026, the travel landscape has shifted from aesthetic "linen-look" wardrobes to high-stakes travel logistics. While traditional vacations focus on… Read More

February 2, 2026

Spiritual Soundscapes: The Dalai Lama’s Historic Victory

The 68th Annual Grammy Awards witnessed a historic moment as the 90-year-old Dalai Lama secured his first-ever win for his… Read More

February 2, 2026

The Urban Forest 2.0: Engineering “Super-Trees” to Survive the Cities of 2030

As global temperatures rise, the transition toward the Urban Forest 2.0 represents a critical evolution in metropolitan planning. The city… Read More

February 2, 2026

Why 2026’s Biggest Fashion Trend Is “Anti-Algorithm” Individuality

The 2026 fashion world is a radical contrast to the pace of hyper-speed trendiness of the "core" aesthetics. After years… Read More

February 2, 2026

Affordable American Cities for Digital Nomads in 2026

Digital nomad cities in the U.S. prioritize low costs, fast internet, and lifestyle perks for remote workers in 2026. Springfield,… Read More

February 2, 2026

How the 2026 FIFA World Cup Fan Zones Are Transforming Downtown Los Angeles

2026 FIFA World Cup fan zones are revitalizing Downtown LA, with the main FIFA Fan Festival at historic Los Angeles… Read More

February 2, 2026

This website uses cookies.

Read More